(by Brian Shilhavy | Vaccine Impact) – As the alternative media is distracted by the unfounded claim that Pfizer is using gain of function technology to develop new variants of COVID for future vaccines, Pfizer is quietly working together with the FDA to build their portfolio of drugs to make up for the loss of income due to decreasing numbers of people willing to continue getting injected with COVID shots.
The evidence that Pfizer controls the FDA continues to mount.
We previously reported how Pfizer virtually came out of nowhere to secure the first FDA authorization for experimental COVID shots in 2020, when the two drug companies that had received the most funding and attention to become the first ones to obtain the FDA nod for a new COVID “vaccine” had been Moderna, with their close links to Anthony Fauci and the NIH, and Astrazenca with its close links to Bill Gates.
Pfizer’s contract with Operation Warp Speed to receive funding for COVID-19 vaccines was different than the other pharmaceutical companies, because it was conditioned on them gaining FDA approval, and it did not include intellectual property rights for the U.S. government.
It appears that this opened the door for them to grant an exclusive deal with Israel in exchange for data on how the experimental shots affected people in Israel, effectively making Israel and its citizens lab rats. See:
And a year before Pfizer became a late entry in the contest to get the first FDA authorization for a COVID shot, Dr. Scott Gottlieb joined the Board of Directors for Pfizer in June of 2019, just two months after he finished his term as Commissioner of the FDA under President Trump.
A year later, Operation Warp Speed awarded Pfizer almost $2 Billion to develop the COVID shot. See:
This week, Pfizer reported that they expect the sale of their COVID-19 shots and their antiviral Paxlovid to dramatically decrease here in 2023:
Despite a plan to jack up the price of Comirnaty to between $110 and $130 per dose when the United States goes to a commercial model this year for COVID-19 vaccines, Pfizer expects revenue from the shot to plummet by 64% in 2023.
Pfizer also expects a 58% decrease in revenue from COVID-19 oral antiviral Paxlovid. The company revealed its 2023 expectations in its fourth quarter and 2022 full-year earnings report on Tuesday.
With the decreases, Pfizer is guiding to a revenue window of $67 billion to $71 billion in 2023.
The projections—which fell short of analyst expectations—put a damper on what might have been a day of celebration as Pfizer reported $100.3 billion in revenue for 2022, after generating $81.3 billion in sales in 2021. (Source.)
But what surprised people in the pharmaceutical industry the most about Pfizer’s forecast for 2023, was that in a “mysterious” FDA approval that was not reported in the media at the end of 2022, Pfizer received expanded use approval for their breast cancer drug Ibrance, and reportedly, the FDA is the one who approached them to expand the use of this drug! Read Full Article >